1979 - The Comp. was incorporated on 11th July, & the Certificate of
Commencement of Business was obtained on 6th November, 1979. It
was promoter jointly by Astra Pharmaceuticals AB, Sweden [Astras]
& IDL Chemicals Ltd., Hyderabad [IDLs].
1980 - The Comp. entered into a technical collaboration with Astra
Pharmaceuticals AB, Sweden for supply for information and
know-how & all manufacturing process & technical data for the
manufacture of basic drugs, formulations, fine chemicals and
- The Comp. undertook to set up a project at Yelahanka,
Bangalore, for manufacture of basic drugs, formulations, fine
& industrial chemicals. Pharmaceuticals & chemicals plant
was commissioned in February 1982.
1982 - 2,000 shares issued to promoters, etc. 24,98,000 shares issued at
par; 6,43,235 shares each allotted to Astra Pharmaceuticals AB,
Sweden & IDL Chemicals, Ltd.; 3,78,830 shares allotted to
Indian directors, shareholders & employees, shareholders and
employees, etc. of Comp. & also that of IDL Chemicals,
limited & 8,32,700 shares offered for public subscription during
1988 - The Comp. launched `SENSORCAINE', a long acting local
anaesthetic for use in surgical anaesthesia & introduced
`THEOBRIC', a combination branco dilator for asthma. The Company
also planned to launch new products based on original research of
Astra in the fields of peptic ulcer, hypertension & asthma.
- The Comp. launched during the year `RESTOMYCIN', an antibiotic
`BROMENYL', a cough expectorant & `FEBRAFEN' a pain & fever
- The Comp. was also in the process of creating in-house
facilities for manufacture of products based on inhalation
therapy & formulation therapy & formulations based on
- The Comp. launched `PROSTODIN', the first protagladin with an
important indication for postpartum haemorage, etc. Several new
products were launched during the year, namely, SELOPRES, BETALOC
DURULES, TRIPRES, SENSORCAINE SPINAL & BRICANYL NEBULISING
SOLUTION. It also launched products based on inhalation therapy
such as `PULMICORTINHALER' BRICANYL INHALER & SPACEHALER.
1991 - The Comp. launched a product in the Prostaglandins range
`PIMIPROST' for promotion of safe motherhood.
1992 - The Comp. launched Prostaglandin `Cerviprime Gel' for
preinduction cervical ripening & `Plendil' a new generation
calcium antagonist. The Comp. proposed to launch `Ramace',
`Rhinocort' & `Imdur'.
1994 - Several new products were launched during the year, namely,
Ramace & Imdur, which strengthen the cardiovascular range of
products. Similarly Rhinocort was introduced which is in the
range of respiratory care products.
1995 - 25,00,000 bonus shares issued in prop. 1:1.
1996 - Two new line of extension namely `Jumbo' pack of Pulmicort &
Bricanyl Inhalers 400 metered doses were introduced in the
respiratory group. A low dose aspirin formation to correct
thromboembolic disorders was launched. Also Imdur 30 mg to
support Imdur 60 mg was introduced.
1997 - A range of new products viz., Xylocaine Spray in pain control
segment, Stop-it in Anti-infective segment, Mimbid in NSAID
segment, Linctus-D & Rhinocort Aqua in Respiratory segment,
Rejois in Maternal health care segment & Cellubril, a stool
- The Comp. established state-of-the-art production facilities
for aerosols & soft gelatin capsules near its formulations
- A joint venture between Astra AB of Sweden & IDL Industries
of Hindujas, Astra-IDL has been the subject of prolonged
litigation between the two promoters.
- A joint venture between the US $ 7-billion Swedish pharmaceutical
major Astra AB & IDL Industries of Hindujas.
1998 - Wipro, Honda Siel Power Products, & Astra-IDL have been
conferred the Analyst Awards, by The Institute of Chartered
Financial Analysts of India [ICFAIs].
- Astra had set up a 100 per cent research facility in Bangalore
three years ago.
1999 - Even as the Hindujas continue to seek new alignments to replace
multinational AstraZeneca in their joint venture Astra-IDL Ltd.
2000 - UB 100 per cent subsidiary, UB Bioteck, has tied up with Astra
IDL Ltd to market its newly-patented anti-obesity nutraceutical.
- Mr. D.E. Udwadia, Director, has been appointed as the Chairman.
2001 - Crisil has placed the `FAA' rating on the fixed deposit programme of the
Comp. on a `rating watch with positive implications'.
- The Comp. upon the acquisition, Astra, Swden now holds 51.50 per cent of
company issued & paid-up equity shares capital. The Comp. is therefore
a subsidiary of Astra, Swden & has become a part of worldwide AstraZeneca Group.
- The Managing Director, Mr. A.R. Hegde, has resigned from the company.
- Astra-IDL Ltd will be renamed AstraZeneca Pharma India Ltd & Mr Lars Walan,
recently designated Managing director, will take over on April 2 from Mr. A.R.
Hegde, MD, who has resigned.
-Ties up with Avestha for research on discovering drug for tuberculosis.
-Makes an open offer to acquire the balance 21,75,050 equity shares of Astrazeneca pharma India Ltd representing 43% stake.
-Government okays FDI proposal for Comp. & Tata Homefinance from 56.69% to 100% accounting for Rs.82 crs.
-Astra Pharma acquires 32800 equity shares of Astrazeneca.
-Astra Pharma & Astrazeneca jointly acquires less than 4% additional equity Astrazeneca Pharma India limited
-Sri Tom McKillop, inaugurates R and D centre in Bangalore at a cost of $40 million.
-Approaches Union government for Exclusive Marketing Rights for new two generation anti-cancer drugs.
-Astrazeneca Pharma India Limited Board accepts resignation of Mr. J G Zetterberg, Director, effective from the close of May 05, 2004.
-AstraZeneca acquires Eli Lilly Vancocin brand
-AstraZeneca Pharma India Ltd has appointed Mr. Ruud Dobber as Director of Company.